Allison Perry

By

College: Arts and Sciences

Glazer Receives Grant to Study Light-Activated Cancer Drugs

Published: Jan 31, 2013

LEXINGTON, Ky. (Jan. 31, 2013) — University of Kentucky assistant professor of chemistry Edith "Phoebe" Glazer has received an American Cancer Society Research Scholar Grant for $715,000 over four years to continue her research into ruthenium-based cancer drugs. These compounds are less toxic to healthy cells than a similar and widely used inorganic drug.

 

Cisplatin is a common platinum-based cancer drug used in a variety of cancer treatments. But while cisplatin kills cancer cells, it also attacks healthy cells, causing debilitating side effects. Ruthenium is another transition metal and belongs to the same group of the periodic table as iron.

 

Previously, the Glazer group developed two new ruthenium complexes designed to kill cancer cells while preserving healthy cells. These complexes are inert in the dark, but when activated with light, they become up to 200 times as toxic, and up to three times as potent as cisplatin against tumor cells.

 

Funded by the American Cancer Society, the new grant will allow Glazer's team to develop improved ruthenium-based compounds and to study their effectiveness. Using the strategy of combining organic ligands as building blocks that assemble around the ruthenium center “core,” a large family of compounds with different structures and properties can be rapidly synthesized. This is in marked contrast to approaches using compounds discovered in nature, called natural products, as chemotherapeutics.

 

Many chemotherapeutics are natural products, but their synthesis is challenging and there are limited chemical modifications that can be made into the molecules. In the ruthenium compounds, the organic components can be easily changed to alter chemical properties and possibly even what types of cells the compounds will enter in the body. The different structures can also potentially prevent the development of drug resistance, as tumors that become resistant to one particular ruthenium drug structure could be vulnerable to another ruthenium compound with a different structure. 

 

The efficacy of the compounds will be tested in different human cancer cell lines and in animal models to determine what cancer types can be treated. The group will also determine the biochemical process by which the compounds kill cells in order to optimize the drugs. The long-term goal of the research is to develop a targeted chemotherapeutic approach with reduced side effects that can be applied to a variety of cancer types.

 

MEDIA CONTACT: Allison Perry, (859) 323-2399 or allison.perry@uky.edu

microscope_closeup_1.jpg
August
 
 
 
 
 
 
1
 
Sat
2
 
Sun
3
 
Mon
4
 
Tue
5
 
Wed
6
 
Thu
7
Curator Tour
Fri
8
 
Sat
9
 
Sun
10
 
Mon
11
 
Tue
12
 
Wed
13
 
Thu
14
 
Fri
15
 
Sat
16
 
Sun
17
 
Mon
18
We Are UK
Tue
19
 
Wed
20
 
Thu
21
Parent and Families Reception
Fri
22
K Team Meeting: K Week Overview
Big Blue U
Campus Ruckus
Getting Around Campus and Beyond
Sat
23
The Late Night Film Series Presents - Fast and Furious 7
K Team Meeting: Lunch and Campus Tour
UK Lex-Mart
Pedalpalooza
Bowman's Bash
Sun
24
Bowman's Bash
K Team Meeting: Dinner with Your K Team
Kentucky at Kroger
Mon
25
K Team Meeting: Common Reading Experience Discussion
Bicycle-Friendly Lexington
Tue
26
First Day of Classes
Don't Steal Bikes, Bro
Understanding Lexington's Bicycle Facilities
First Day of Classes
Wildcat Wellness Meditation
Wed
27
The Late Night Film Series Presents - The Wind Rises
The Late Night Film Series Presents - Avengers: Age of Ultron
Adjusting to College
Wildcat Wellness - Yoga for Relaxation
Painting and Mocktails
Terrace Time Out at the Hilary J. Boone Center
Thu
28
The Late Night Film Series Presents - Divergent
The Late Night Film Series Presents - Ex Machina
Wildcat Block Watch
Chapel Talk: Faith and Science in an Evolving World
Royalty Showcase
Fri
29
 
Sat
30
 
Sun
31
Wildcat Wellness Expressions - Inspiration Object
UK Mock Trial Informational Meeting
Mon
 
 
 
 
 
Reset Page